Skip to main content
Contact Us
Subscribe
E-Edition
55°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Myriad Genetics, Inc.
< Previous
1
2
3
Next >
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
November 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
ILMN
MYGN
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
November 19, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
November 13, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
November 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
November 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
October 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
October 08, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
October 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
October 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
September 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Host Investor Event on October 9, 2024
September 05, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
GSK
MYGN
PSNL
QGEN
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
PSNL
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
QGEN
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Tickers
MYGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.